Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J. van der Horst, Tuna Mutis, A. Vera de Jonge et al.|Blood Cancer Journal|2021Cited by 95
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR designEsther Drent, Tuna Mutis|PLoS ONE|2018Cited by 73
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell MalignanciesHilma J. van der Horst, Martine E.D. Chamuleau, Inger S. Nijhof et al.|Cancers|2020Cited by 72
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignanciesSimone C. Oostindie, Esther C.W. Breij, Hilma J. van der Horst et al.|Blood Cancer Journal|2020Cited by 70
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clusteringSimone C. Oostindie, Ronald P. Taylor, Hilma J. van der Horst et al.|Haematologica|2019Cited by 62